PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 92506

Title: Glucagon-like-peptide-1 receptor agonists (GLP-1RAs) and the management of type 2 diabetes - backwards and forwards.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05247977

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor

Reviewer's Country/Territory: Saudi Arabia

Author's Country/Territory: Australia

Manuscript submission date: 2024-01-28

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2024-02-01 08:35

Reviewer performed review: 2024-02-01 08:44

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

no specific comments on editorial letter

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 92506

Title: Glucagon-like-peptide-1 receptor agonists (GLP-1RAs) and the management of type 2 diabetes - backwards and forwards.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05278434

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Australia

Manuscript submission date: 2024-01-28

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2024-01-29 08:14

Reviewer performed review: 2024-02-06 10:18

Review time: 8 Days and 2 Hours

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The logic of this Editorial is sound. The structure and content of the article are well-organized, allowing readers to gain a clear understanding of the importance and application of GLP-1RA. The manuscript covers the historical development, pharmacological actions, clinical applications, and impact on patient management of GLP-1 receptor agonists. The authors mention the role of GLP-1 receptor agonists in blood glucose control, weight management, cardiovascular protection, and the challenges such as delayed gastric emptying before surgery. Additionally, the article emphasizes the importance of personalized treatment strategies to better utilize GLP-1 receptor agonists. Overall, this article seems to provide a comprehensive overview and insights into the clinical application of GLP-1 receptor agonists, aiding readers in understanding the latest developments in this field.

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 92506

Title: Glucagon-like-peptide-1 receptor agonists (GLP-1RAs) and the management of type 2 diabetes - backwards and forwards.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04152279

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Australia

Manuscript submission date: 2024-01-28

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2024-01-29 17:29

Reviewer performed review: 2024-02-07 03:31

Review time: 8 Days and 10 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

GLP-1RAs have revolutionized the management of type 2 diabetes. These medications lower blood sugar without causing hypoglycemia, and they also hold promise for cardiovascular and renal protection. This article provides a detailed discussion of the limitations of conventional therapies for type 2 diabetes, explores the current status of GLP-1RAs treatment, and addresses potential issues. The editorial, based on the latest research, offers a fresh perspective with significant clinical implications. However, there are still some unresolved issues. Therefore, it is recommended to summarize and emphasize the role of GLP-1RAs in the treatment of type 2 diabetes at the end of the article.